Mcdonald Partners LLC Has $2.93 Million Stake in Pfizer Inc. (NYSE:PFE)

Mcdonald Partners LLC boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 9.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,296 shares of the biopharmaceutical company's stock after buying an additional 9,963 shares during the quarter. Mcdonald Partners LLC's holdings in Pfizer were worth $2,926,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. State Street Corp increased its holdings in shares of Pfizer by 1.2% during the third quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company's stock worth $8,405,930,000 after buying an additional 3,405,539 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Pfizer by 11.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock worth $3,766,366,000 after acquiring an additional 12,864,343 shares during the last quarter. Geode Capital Management LLC increased its holdings in Pfizer by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock valued at $3,392,342,000 after purchasing an additional 1,855,419 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Pfizer by 22.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock valued at $1,101,713,000 after purchasing an additional 6,977,587 shares during the last quarter. Finally, Van ECK Associates Corp boosted its stake in Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company's stock worth $564,739,000 after purchasing an additional 4,726,549 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 1.6 %

Shares of Pfizer stock traded up $0.42 during trading on Friday, reaching $26.32. 54,560,140 shares of the company were exchanged, compared to its average volume of 38,524,395. The business has a 50-day moving average price of $26.30 and a 200-day moving average price of $27.42. The firm has a market capitalization of $149.14 billion, a price-to-earnings ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.10 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.54%. Pfizer's dividend payout ratio (DPR) is 121.99%.

Analysts Set New Price Targets

PFE has been the subject of a number of research reports. StockNews.com lowered Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Evercore ISI upgraded shares of Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Finally, Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They set an "underperform" rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.